Pan-ELR+ CXC chemokine antibodies and il-23p19 antibodies for the treatment of ulcerative colitis
TW202631190APending Publication Date: 2026-08-01ELI LILLY & CO
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- TW · TW
- Patent Type
- Applications
- Current Assignee / Owner
- ELI LILLY & CO
- Filing Date
- 2025-09-12
- Publication Date
- 2026-08-01
Abstract
Provided herein are methods and uses of antibodies that bind to ELR+ CXC chemokines in combination with antibodies that bind to human IL-23p19 for the treatment of ulcerative colitis. Also provided are doses and dosing regimens for the methods and uses of antibodies that bind to ELR+ CXC chemokines in combination with antibodies that bind to human IL-23p19 for the treatment of ulcerative colitis.
Need to check novelty before this filing date? Find Prior Art